FN2 Earnings Intelligence
CVS Health Corp. financials
CVS Health Corp. (CVS) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $9,408 | $12,945 | $8,196 | $8,586 | $8,453 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $292,111 | $322,467 | $357,776 | $372,809 | $402,067 | $409,044.3 | $426,275.9 |
| % Growth | 8.7% | 10.4% | 10.9% | 4.2% | 7.8% | 1.7% | 4.2% |
| Gross Profit | $116,308 | $125,575 | $140,678 | $166,522 | $180,900 | - | - |
| % Margin | 39.8% | 38.9% | 39.3% | 44.7% | 45.0% | - | - |
| EBITDA | $17,705 | $11,993 | $18,109 | $13,113 | $9,266 | - | - |
| % Margin | 6.1% | 3.7% | 5.1% | 3.5% | 2.3% | - | - |
| Net Income | $7,910 | $4,149 | $8,344 | $4,614 | $1,768 | - | - |
| % Margin | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% | - | - |
| Diluted EPS | $5.95 | $3.14 | $6.47 | $3.66 | $1.39 | $7.45 | $8.43 |
| % Growth | 9.0% | -47.2% | 106.1% | -43.4% | -62.0% | 435.9% | 13.2% |
| Operating Cash Flow | $18,265 | $16,177 | $13,426 | $9,107 | $10,639 | - | - |
| CapEx | $2,520 | $2,727 | $3,031 | $2,781 | $2,832 | - | - |
| Free Cash Flow | $15,745 | $13,450 | $10,395 | $6,326 | $7,807 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $292,111 | $322,467 | $357,776 | $372,809 | $402,067 | $409,044.3 | $426,275.9 |
| Gross Profit | $116,308 | $125,575 | $140,678 | $166,522 | $180,900 | - | - |
| EBITDA | $17,705 | $11,993 | $18,109 | $13,113 | $9,266 | - | - |
| Net Income | $7,910 | $4,149 | $8,344 | $4,614 | $1,768 | - | - |
| Diluted EPS | $5.95 | $3.14 | $6.47 | $3.66 | $1.39 | $7.45 | $8.43 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9,408 | $12,945 | $8,196 | $8,586 | $8,453 |
| Short-term Debt | - | - | $200 | $2,119 | $0 |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $18,265 | $16,177 | $13,426 | $9,107 | $10,639 |
| Capital Expenditure | $2,520 | $2,727 | $3,031 | $2,781 | $2,832 |
| Free Cash Flow | $15,745 | $13,450 | $10,395 | $6,326 | $7,807 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 8.7% | 10.4% | 10.9% | 4.2% | 7.8% |
| Gross Margin | 39.8% | 38.9% | 39.3% | 44.7% | 45.0% |
| EBITDA Margin | 6.1% | 3.7% | 5.1% | 3.5% | 2.3% |
| Net Margin | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| FCF Margin | 5.4% | 4.2% | 2.9% | 1.7% | 1.9% |
| Diluted EPS Growth | 9.0% | -47.2% | 106.1% | -43.4% | -62.0% |